AVEO Oncology has appointed Dr Nikhil Mehta as senior vice president or regulatory and quality assurance, a role that will see him oversee all aspects of regulatory, quality and technical operations for the company’s portfolio.
Dr Mehta brings over 25 years’ experience in biotechnology and pharmaceutical industries to AVEO and most recently, Dr Mehta served as executive vice president and chief regulatory strategies at Tang Capital Management, where he was involved in establishing two biopharmaceutical companies.
Prior to Tang Capital, he served as global head of regulatory affairs at Baxalta and before that, he was vice president, global regulatory affairs, oncology, haematology, immunology and diagnostics at Merck & Co.
He has also held roles for Shire, Bristol-Myers Squibb and Hoffman-La Roche.
Michael Baily, president and chief executive officer, AVEO, said: “Dr Mehta brings to AVEO a depth of experience in regulatory affairs and oncology that we believe will be invaluable as we plan and advance our US registration strategy for tivozanib as a potential treatment for renal cell carcinoma.”
“I anticipate Dr Mehta’s integration into the AVEO team will be seamless and rapidly productive and we look forward to working with him.”